These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 23531479

  • 1. Regulatory T cells contribute to rosuvastatin-induced cardioprotection against ischemia-reperfusion injury.
    Ke D, Fang J, Fan L, Chen Z, Chen L.
    Coron Artery Dis; 2013 Jun; 24(4):334-41. PubMed ID: 23531479
    [Abstract] [Full Text] [Related]

  • 2. Targeted deletion of regulatory T cells attenuates the protective effects of myocardial ischemic preconditioning in rats.
    Ke D, Fang J, Fan L, Chen L.
    Scand Cardiovasc J; 2015 Feb; 49(1):64-71. PubMed ID: 25580940
    [Abstract] [Full Text] [Related]

  • 3. [Rosuvastatin enhances the protective effects of ischemic postconditioning on myocardial ischaemia-reperfusion injury in type 2 diabetic rat].
    CAI W, FANG J, CHEN ZY, LIN YL, WU LM, CHEN LL.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Sep; 38(9):814-8. PubMed ID: 21092651
    [Abstract] [Full Text] [Related]

  • 4. Rosuvastatin, a new generation 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces ischemia/reperfusion-induced spinal cord tissue injury in rats.
    Ucak A, Onan B, Güler A, Sahin MA, Kılıçkaya O, Oztaş E, Uysal B, Arslan S, Yılmaz AT.
    Ann Vasc Surg; 2011 Jul; 25(5):686-95. PubMed ID: 21724106
    [Abstract] [Full Text] [Related]

  • 5. Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation.
    Bulhak A, Roy J, Hedin U, Sjöquist PO, Pernow J.
    Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H3158-63. PubMed ID: 17322412
    [Abstract] [Full Text] [Related]

  • 6. Single-dose rosuvastatin ameliorates lung ischemia-reperfusion injury via upregulation of endothelial nitric oxide synthase and inhibition of macrophage infiltration in rats with pulmonary hypertension.
    Matsuo S, Saiki Y, Adachi O, Kawamoto S, Fukushige S, Horii A, Saiki Y.
    J Thorac Cardiovasc Surg; 2015 Mar; 149(3):902-9. PubMed ID: 25454916
    [Abstract] [Full Text] [Related]

  • 7. N,N-dimethylsphingosine attenuates myocardial ischemia-reperfusion injury by recruiting regulatory T cells through PI3K/Akt pathway in mice.
    Fang J, Hu F, Ke D, Yan Y, Liao Z, Yuan X, Wu L, Jiang Q, Chen L.
    Basic Res Cardiol; 2016 May; 111(3):32. PubMed ID: 27048490
    [Abstract] [Full Text] [Related]

  • 8. Rosuvastatin preconditioning provides neuroprotection against spinal cord ischemia in rats through modulating nitric oxide synthase expressions.
    Die J, Wang K, Fan L, Jiang Y, Shi Z.
    Brain Res; 2010 Jul 30; 1346():251-61. PubMed ID: 20513366
    [Abstract] [Full Text] [Related]

  • 9. Rosuvastatin given during reperfusion decreases infarct size and inhibits matrix metalloproteinase-2 activity in normocholesterolemic and hypercholesterolemic rabbits.
    D'Annunzio V, Donato M, Erni L, Miksztowicz V, Buchholz B, Carrión CL, Schreier L, Wikinski R, Gelpi RJ, Berg G, Basso N.
    J Cardiovasc Pharmacol; 2009 Feb 30; 53(2):137-44. PubMed ID: 19188835
    [Abstract] [Full Text] [Related]

  • 10. Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion.
    Weinberg EO, Scherrer-Crosbie M, Picard MH, Nasseri BA, MacGillivray C, Gannon J, Lian Q, Bloch KD, Lee RT.
    Am J Physiol Heart Circ Physiol; 2005 Apr 30; 288(4):H1802-9. PubMed ID: 15563531
    [Abstract] [Full Text] [Related]

  • 11. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor.
    Jones SP, Gibson MF, Rimmer DM, Gibson TM, Sharp BR, Lefer DJ.
    J Am Coll Cardiol; 2002 Sep 18; 40(6):1172-8. PubMed ID: 12354446
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level.
    Bulhak AA, Gourine AV, Gonon AT, Sjöquist PO, Valen G, Pernow J.
    Acta Physiol Scand; 2005 Feb 18; 183(2):151-9. PubMed ID: 15676056
    [Abstract] [Full Text] [Related]

  • 14. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts.
    Di Napoli P, Taccardi AA, Grilli A, De Lutiis MA, Barsotti A, Felaco M, De Caterina R.
    Cardiovasc Res; 2005 Jun 01; 66(3):462-71. PubMed ID: 15914111
    [Abstract] [Full Text] [Related]

  • 15. Combined postconditioning with ischemia and α7nAChR agonist produces an enhanced protection against rat myocardial ischemia reperfusion injury.
    Xiong J, Yuan YJ, Xue FS, Wang Q, Li S, Liao X, Liu JH, Chen Y, Li RP.
    Chin Med J (Engl); 2012 Jan 01; 125(2):326-31. PubMed ID: 22340568
    [Abstract] [Full Text] [Related]

  • 16. Single administration of the CXC chemokine-binding protein Evasin-3 during ischemia prevents myocardial reperfusion injury in mice.
    Montecucco F, Lenglet S, Braunersreuther V, Pelli G, Pellieux C, Montessuit C, Lerch R, Deruaz M, Proudfoot AE, Mach F.
    Arterioscler Thromb Vasc Biol; 2010 Jul 01; 30(7):1371-7. PubMed ID: 20413731
    [Abstract] [Full Text] [Related]

  • 17. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism.
    Liuni A, Luca MC, Gori T, Parker JD.
    J Am Coll Cardiol; 2010 Mar 09; 55(10):1002-6. PubMed ID: 20202516
    [Abstract] [Full Text] [Related]

  • 18. The endothelial-protective effects of HMG-CoA reductase inhibition in the setting of ischemia and reperfusion injury.
    Liuni A, Luca MC, Gori T, Parker JD.
    Clin Hemorheol Microcirc; 2010 Mar 09; 45(2-4):161-7. PubMed ID: 20675896
    [Abstract] [Full Text] [Related]

  • 19. [A treatment with rosuvastatin induced a reduction of arterial pressure and a decrease of oxidative stress in spontaneously hypertensive rats].
    Sicard P, Lauzier B, Oudot A, Busseuil D, Collin B, Duvillard L, Moreau D, Vergely C, Rochette L.
    Arch Mal Coeur Vaiss; 2005 Mar 09; 98(7-8):804-8. PubMed ID: 16220751
    [Abstract] [Full Text] [Related]

  • 20. Protective effect of phloroglucinol against myocardial ischaemia-reperfusion injury is related to inhibition of myeloperoxidase activity and inflammatory cell infiltration.
    Li TT, Zhang YS, He L, Li NS, Peng J, Li YJ.
    Clin Exp Pharmacol Physiol; 2011 Jan 09; 38(1):27-33. PubMed ID: 21039756
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.